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Abstract
Introduction
Prediction models for gestational hypertension and preeclampsia have been developed with
data and assumptions from developed countries. Their suitability and application for low
resource settings have not been tested. This review aimed to identify and assess the meth-
odological quality of prediction models for gestational hypertension and pre-eclampsia with
reference to their application in low resource settings.
Methods
Using combinations of keywords for gestational hypertension, preeclampsia and prediction
models seven databases were searched to identify prediction models developed with mater-
nal data obtained before 20 weeks of pregnancy and including at least three predictors
(Prospero registration CRD 42017078786). Prediction model characteristics and perfor-
mance measures were extracted using the CHARMS, STROBE and TRIPOD checklists.
The National Institute of Health quality assessment tools for observational cohort and cross-
sectional studies were used for study quality appraisal.
Results
We retrieved 8,309 articles out of which 40 articles were eligible for review. Seventy-seven
percent of all the prediction models combined biomarkers with maternal clinical characteris-
tics. Biomarkers used as predictors in most models were pregnancy associated plasma pro-
tein-A (PAPP-A) and placental growth factor (PlGF). Only five studies were conducted in a
low-and middle income country.
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Conclusions
Most of the studies evaluated did not completely follow the CHARMS, TRIPOD and
STROBE guidelines in prediction model development and reporting. Adherence to these
guidelines will improve prediction modelling studies and subsequent application of predic-
tion models in clinical practice. Prediction models using maternal characteristics, with good
discrimination and calibration, should be externally validated for use in low and middle
income countries where biomarker assays are not routinely available.
Introduction
Hypertensive disorders of pregnancy (HDPs) are important causes of maternal morbidity and
mortality globally but the burden is greatest in low- and middle-income countries (LMIC) [1–
3]. These disorders of pregnancy include gestational hypertension, preeclampsia and eclampsia
and are characterized by an increase in blood pressure and multi-organ derangements which
range from mild to severe [4]. There is no known cure but daily administration of low dose
aspirin early in the first trimester has been shown to reduce the incidence and the severity of
preeclampsia [5–8]. Preeclampsia is a major indication for preterm delivery, accounting for
about 15% of all preterm deliveries [9–13] and is a cause of increased healthcare costs through
the prolonged stay of the mother or newborn in intensive care units [14].
Prediction models provide estimates of the probability or risk of the future occurrence of a
particular outcome or event in individuals at risk of such an event [15]. Prediction models
have also been used to identify women at high risk of developing HDPs later in pregnancy so
as to provide for closer monitoring from early pregnancy onwards, including low dose aspirin
prophylaxis [5–8] which has been shown to reduce the risk of developing preeclampsia.
The aim of this systematic review was to evaluate the performance of multivariate predic-
tion models to address the question of the effectiveness of prediction models in identifying
pregnant women at risk of gestational hypertension and preeclampsia. The objectives were to
identify prediction models for gestational hypertension and preeclampsia; assess the methodo-
logical quality of the studies to develop and externally validate the prediction models using the
CHARMS [16] checklist; and to identify prediction models that can be applied in low and mid-
dle income country settings.
Methods
This study was conducted using the critical appraisal and data extraction for systematic
reviews of prediction modelling studies (CHARMS) [16], strengthening the reporting of obser-
vational studies in epidemiology (STROBE) [17] and the transparent reporting of a multivari-
able prediction model for individual prognosis or diagnosis (TRIPOD) [18] checklists. The
Population, Intervention, Comparator and Outcome (PICO) format for the review was as fol-
lows: P (pregnant women), I (prediction models), C (none) and O (gestational hypertension
or preeclampsia). The study protocol was registered with the Prospero International Prospec-
tive Register of Systematic Reviews (CRD 42017078786).
Search strategy
A comprehensive systematic literature search with was conducted in PubMed/Medline,
Embase, Cochrane Library, Web of Science and CINAHL databases from their inception
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through 18 September 2017. The search was updated to 15 October 2019 (DLV,EA). The
MeSH database, EMTREE subject headings and CINAHL subject headings were used to con-
struct the search strategy along with author keywords and general keywords. In addition, an
electronic hand search was conducted in a number of journals from 10th September through
25th September, 2017 and from October 1 to October 15, 2019. Finally, grey literature was
searched using the New York Academy of Medicine Grey Literature, OCLC’s OAISTER, and
Open Grey databases.
The search strategy is provided as a supplementary file (S1 Data).
Eligibility/Inclusion criteria
Cohort studies, nested-case control studies and randomized controlled trials were eligible for
inclusion in the study. Case-control, cross-sectional, animal studies, bio-molecular studies, let-
ters, reviews and case reports were excluded because for prediction modeling studies we require
absolute risks whereas case-control or cross-sectional studies only give relative risks. The pri-
mary outcomes for the included studies were gestational hypertension and preeclampsia.
Definition of terms
Gestational hypertension was defined as elevated systolic blood pressure equal to or greater
than 140mmHg and/or diastolic blood pressure equal or greater than 90mmHg on at least two
occasions four hours apart and appearing for the first time after 20 weeks of gestation without
proteinuria [4]. Pre-eclampsia was defined as gestational hypertension with proteinuria of
300mg or more in a 24-hour urine sample or spot urine protein/creatinine ratio of 30mg/
mmol [4]. Pre-eclampsia was further divided into early-onset preeclampsia (requiring preterm
delivery before 34 weeks gestation) and late-onset preeclampsia (with delivery at or after 34
weeks gestation or later) as an outcome by some studies [19–24].
A prediction model [25] was defined as a logistic regression formula or a survival model
with three or more predictors that could be used to estimate risk probabilities for individual
patients or to distinguish between groups of patients of different risks.
Screening methods for study identification
Two reviewers (EA, MAC) independently assessed the titles and abstracts of the search results
to select relevant papers for further screening. After removal of duplicates, the articles were
obtained for screening/reading of the full text after which eligible papers were selected for
inclusion in the systematic review. Discrepancies between the reviewers were resolved through
consensus.
Data extraction and management
Data extraction of the identified studies was done by using the CHARMS checklists (EA).
Extracted data were checked (MAC) and disagreements were resolved by consensus (EA,
MAC). In case of disagreement a third reviewer (KKG) was consulted. Studies were analysed
qualitatively given the large variability of the studies included.
The following categories were extracted: authors, journal, year of publication, region or
place where study was conducted, period of data collection, study design, inclusion and exclu-
sion criteria, the sample size of the derivation cohort and/or the validation cohort, the gesta-
tional age at which women were enrolled into the study and the number of outcomes. Other
information extracted were the number and types of predictors, the target population for
whom the prediction model is intended for, the handling of missing data, the modeling
PLOS ONE Systematic review of prediction models.
PLOS ONE | https://doi.org/10.1371/journal.pone.0230955 April 21, 2020 3 / 24
method used, the model selection method, the handling of continuous data, the method used
for internal validation and whether or not an external validation was done.
Quality assessment
Quality of the studies was assessed using the CHARMS, STROBE and TRIPOD checklists and
the National Institute of Health (NIH) [26] quality assessment tools for observational cohort
and cross-sectional studies was independently assessed by two authors (EA, MAC). The NIH
quality assessment tools focus on concepts that are key for critical appraisal of the internal
validity of a study. The tool uses a 14-item checklist to assess the study design, inclusion crite-
ria, outcome and variable description and collection and loss to follow up among others. Each
item is scored as yes, no or other (not reported, not applicable or cannot determine). The tool
also provides guidance on grading the studies as good, fair or poor. The studies were finally
graded for risk of bias as”low” if risk of bias was unlikely, “moderate” if there were no essential
flaws, but not all criteria had been satisfied and “high” if there were flaws in one or more
important items. We adapted the tool and used 13 out of the 14 items, because one item, “for
exposures that can vary in amount or level, did the study examine different levels of the expo-
sure as related to the outcome (e.g., categories of exposure, or exposure measured as continu-
ous variable)?” was not relevant to our review.
Meta-analysis
We performed a meta-analysis on 22 of the studies with preeclampsia as outcome, using the
MedCalc Statistical Software version 19.1.7 (MedCalc Software Ltd, Ostend, Belgium; https://
www.medcalc.org; 2020). These 22 studies had fully reported the area under the curve with
95% confidence intervals. We used the random effects model.
Results
Fig 1 shows the flow diagram for inclusion and exclusion of relevant articles. The search
yielded 8,309 papers. After removing 3,002 duplicates, 5307 papers were screened further for
relevance and 196 papers selected for full text assessment. 156 articles were excluded based on
reasons such as not presenting a prediction model, measurement of predictors done after 20
weeks of gestation and the prediction outcome not being preeclampsia or gestational hyper-
tension. Finally 40 papers, published between 2000 and 2019, were selected for the review.
Prediction models for gestational hypertension and pre-eclampsia
All forty studies included in this review were conducted between 2000 and 2019. Table 1 gives
an overview of important parameters of the selected studies. The studies have been grouped in
the following order: maternal characteristics only, maternal characteristics and uterine artery
Doppler, maternal characteristics with biomarkers and maternal characteristics with biomark-
ers and uterine artery Doppler.
Twelve studies were conducted in the United Kingdom, eight in the United States of Amer-
ica, four each in Australia, Spain and Italy and three in New Zealand. Two studies were done
in the Netherlands, Ireland, Brazil, Chile and Ghana with one each in Japan, China, Germany,
Norway, Bulgaria, Greece, Belgium and Canada.
Most of the studies were prospective cohort studies (33/40 = 82.5%), four were retrospective
cohort studies (10%), three were nested-case control studies (7.5%) and one study combined a
retrospective and prospective cohort design for data collection. The prediction models were
derived through logistic regression or parametric survival modeling.
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The gestational age at inclusion into the studies ranged between eight and twenty weeks. All
the gestational ages were confirmed by ultrasound. The sample size for the studies ranged
between 173 and 35,948. The events per variable in the studies ranged between 2.1 and 88.2.
Seventy seven percent of all the prediction models combined biomarkers with maternal
clinical characteristics. Body mass index (BMI) was the most frequently used predictor (19/
40). Other maternal clinical predictors used in the models were first trimester systolic blood
Fig 1. Flow diagram for inclusion and exclusion of relevant articles.
https://doi.org/10.1371/journal.pone.0230955.g001
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Table 1. Overview of prediction models.
Study Study design Centre Study population Outcome Women, n
(outcome events;
predictors)
Number of events
per variable
Mello et al,
2002 [14]
Prospective cohort Single Italian (Caucasian) Preeclampsia 187 (47; 8)) 5.9
Poon, et al,
2010 [34]
Prospective cohort Single United Kingdom (multi
racial)
Early Preeclampsia, late
preeclampsia, gestational
hypertension.
8366 (165; 8) 20.6
Muto et al,
2016 [42]
Prospective cohort Single Japanese Preeclampsia, gestational
hypertension
1986 (50; 6) 8.3
Kuijk et al,
2014 [32]
Combined prospective and
retrospective cohort
Multi centre Dutch (multi racial) Early onset preeclampsia 229(15; 5) 3
Poon et al,
2008 [35]
Prospective cohort Single United Kingdom (multi
racial)
Preeclampsia, gestational
hypertension
5193 (104; 5) 5
Benko et al,
2019 [53]
Prospective cohort Multicentre United Kingdom,
Bulgaria, Spain (Multi
racial)
Preeclampsia in twin
pregnancies.
2219 (171;11) 15.5
Boutin et al,
2018 [58]
Prospective cohort Single Canadian (multi
ethnic)
Preterm preeclampsia, all
preeclampsia.
4612 (232;6) 38.7
Antwi et al,
2017 [47]
Prospective cohort Multi centre Ghanaian Gestational hypertension 2529 (261; 6) 43.5
Becker Rolf,
2011 [49]
Retrospective cohort Single German (Caucasian) Preeclampsia, preterm
delivery, intrauterine fetal
growth restriction, placental
abruption, intrauterine fetal
death, early neonatal fetal
death (within first week of
postnatal life)
15,855(172; 6) 28.7
North et al,
2011 [48]
Prospective cohort Multi centre United Kingdom, New
Zealand, Ireland,
Australia (multi racial)
Preeclampsia 3529(186; 13) 14.3
Sepulvelda-
Martinez et al,
2019 [56]
Nested case control
(Prospective cohort)
Single Chilean Preterm preeclampsia, term
preeclampsia.
1756 (49; 7) 7
Myatt L. et al,
2012 [50]
Prospective cohort Multi centre American (multi racial) Preeclampsia 2,394 (176; 7) 25.1
Goetzinger
et al,2010 [51]
Retrospective cohort Single American (multi racial) Preeclampsia 3716 (293; 5) 58.6
Odibo et al,
2011 [52]
Retrospective cohort Single American (multi racial) Preeclampsia 452(42;6) 7
Kuijk et al.
2011 [19]
Prospective cohort Multi centre Dutch (multi racial) Early onset preeclampsia 407 (28; 5) 5.6
Stamilio et al,
2000 [31]
Retrospective cohort Single American (multi racial) Preeclampsia, Severe
preeclampsia
1998 (49; 4) 12.2
Gabbay-Benziv
et al, [23]
Prospective cohort Multi centre American (multi racial) Preeclampsia 2433 (108; 5) 21.6
Allen et al,
2017 [44]
Prospective cohort Single United Kingdom (multi
racial)
Preeclampsia, gestational
hypertension, small-for-
gestational age
1045 (56; 5) 11.2
Mello et al,
2001 [45]
Prospective cohort Single Italian (Caucasian) Pregnancy induced
hypertension
303 (76; 9) 8.4
Antwi et al,
2018 [60]
Prospective cohort Multi centre Ghananian Gestational hypertension 373 (25;6) 4.1
Zhang et al,
2019 [57]
Prospective cohort Single Chinese Early preeclampsia, late
preeclampsi, small-for-
gestational age baby.
3270 (43;8) 5.3
(Continued)
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Table 1. (Continued)
O’Gorman
et al, 2016 [27]
Prospective cohort Single United Kingdom (multi
racial)
Preterm Preeclampsia, term
preeclampsia.
35,948 (1058; 15) 70.5
Pare´ et al, 2014
[28]
Prospective cohort Multi centre American (multi racial) Preeclampsia, gestational
hypertension, HELLP�
syndrome, eclampsia
2,637 (431; 8) 29.6
Moon et al,
2015 [29]
Prospective cohort Single United Kingdom (multi
racial)
Preeclampsia 1177(102;11) 9.3
Park et al, 2013
[30]
Prospective cohort Multi centre Australian (multi
racial)
Early Preeclampsia, late
preeclampsia, gestational
hypertension.
3066 (83; 7) 11.9
Kenny et al,
2014 [33]
Prospective cohort Multi center New Zealand,
Australia, United
Kingdom, Ireland
(multi racial)
Early onset preeclampsia,
Preeclampsia
3529 (278; 5) 55.6
Poon et al,
2009 [21]
Prospective cohort Single United Kingdom (multi
racial)
Early Preeclampsia, Late
preeclampsia, gestational
hypertension.
7797 (157; 8) 19.6
Herraiz et al,
2009 [36]
Prospective cohort Single Spanish (multi racial) Early Preeclampsia, late
preeclampsia
152 (20;4) 5
Di Lorenzo
et al, 2012 [37]
Prospective cohort Single Italian (multi racial) Early onset preeclampsia,
late onset preeclampsia,
overall Preeclampsia,
gestational hypertension
2118 (preeclampsia
(25), gestational
hypertension (46);
8)
3.1
Goetzinger
et al, 2014 [38]
Prospective cohort Single American (multi racial) Preeclampsia 578(49; 6) 8.1
Crovetto et al,
2014 [39]
Nested case-control
(Prospective cohort)
Single Spanish (multi racial) Early Preeclampsia, late
preeclampsi
5759 (112; 10) 11.2
Gallo et al,
2016 [40]
Prospective cohort Multi centre United Kingdom (multi
racial)
Preterm Preeclampsia, term
preeclampsia.
7748 (268; 11) 24.4
Skrastad et al,
2015 [41]
Prospective cohort Single Norway Preeclampsia, gestational
hypertension
541 (21; 11) 1.9
Antonio et al,
2017 [43]
Prospective cohort Single Brazilian (multi racial) Preeclampsia, gestational
hypertension
617 (34; 4) 8.5
Parra-Cordero
et al, 2013 [24]
Nested case-control
(Prospective cohort)
Single Chilean Early onset Preeclampsia,
late onset preeclampsia.
2619 (83; 4) 20.7
Myers et al,
2013 [20]
Prospective cohort Multi centre United Kingdom, New
Zealand, Australia
(multi racial)
Preterm preeclampsia 3529 (55; 7) 7.9
Baschat et al,
2014 [46]
Prospective cohort Multi centre American (multi racial) Early onset preeclampsia,
Preeclampsia
2441 (108; 5) 21.6
Scazzocchio,
et al, 2017 [54]
Prospective cohort Single Spain Early onset preeclampsia,
late onset preeclampsia.
4203 (169; 7) 24.1
Wright et al,
2019 [55].
Prospective cohort Multicentre United Kingdom,
Spain, Belgium, Italy,
Greece
Early preeclampsia, pre-term
preeclampsia. All
preeclampsia.
61,174 (1770; 11) 160.9
Lobo et al,
2019 [59]
Prospective cohort Single Brazil (multi ethnic) Preterm Preeclampsia, term
preeclampsia
617 (34;8) 4.2
Study Predictors Type of model Internal validation External validation Calibration (p-
value Hosmer-
Lemeshow test or
calibration plot)
Model
performance:
PPV, NPV,
Sensitivity,
Specificity,
Mello et al,
2002 [14]
Maternal characteristics Logistic
regression
Yes No No Yes
Poon, et al,
2010 [34]
Maternal characteristics Logistic
regression
Not stated No No Yes
(Continued)
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Table 1. (Continued)
Muto et al,
2016 [42]
Maternal characteristics Logistic
regression
Not stated No No Yes
Kuijk et al,
2014 [32]
Maternal characteristics Logistic
regression
Not applicable Yes. Study externally
validated a previously
developed prediction model
Yes. Calibration
plot and Hosmer-
Lemeshow
goodnesss -of-fit
test.
Yes
Poon et al,
2008 [35]
Maternal characteristics Logistic
regression
Not stated No No Yes
Benko et al,
2019
Maternal characteristics Parametric
survival model
Not stated Yes Yes Yes
Boutin et al,
2018
maternal age, BMI,
hypertension, chronic
inflammatory disease,
ovulation induction, in vitro
fertilization
Proportional
hazard model
Not stated No No Yes
Antwi et al,
2017
Maternal weight, height,
parity, diastolic blood
pressure, history of
gestational hypertension,
family history of
hypertension
Logistic
regression
Bootstrapping Yes No No
Becker Rolf,
2011 [49]
Maternal characteristics,
uterine artery pulsatility
index
Logistic
regression
Not stated Yes No No
North et al,
2011 [48]
Maternal characteristics,
uterine artery pulsatility
index
Logistic
regression
Cross validation No Yes. Calibration
plot
Yes
Sepulveda-
Martinez et al,
2019
maternal characteristics,
uterine artery pulsatility
index
Logistic
regression
Not stated No No Yes
Myatt L. et al,
2012 [50]
Maternal characteristics,
serum biomarkers
Logistic
regression
Not stated No No Yes
Goetzinger
et al,2010 [51]
Maternal characteristics,
serum biomarkers
Logistic
regression
Not stated No No Yes
Odibo et al,
2011 [52]
Maternal characteristics,
serum biomarkers
Logistic
regression
Not stated No No Yes
Kuijk et al.
2011 [19]
Maternal characteristics,
fasting blood glucose.
Logistic
regression
Bootstrapping No Yes. Hosmer-
Lemeshow
goodnesss-of-fit
test.
Yes
Stamilio et al,
2000 [31]
Maternal characteristics,
serum biomarkers.
Logistic
regression
Not stated No No Yes
Gabbay-Benziv
et al, [23]
Maternal characteristics,
biomarkers.
Logistic
regression
Not stated No No Yes
Allen et al,
2017 [44]
Maternal characteristics,
biomarkers.
Logistic
regression
Not stated No No Yes
Mello et al,
2001 [45]
Maternal characteristics,
hematological and
biochemical indices.
Logistic
regression
Cross validation No No Yes
Antwi et al,
2018 [47]
Maternal characteristics,
serum biomarkers.
Logistic
regression
Bootstrapping Yes Yes. Calibration
plot
Yes
Zhang et al,
2019
BMI, ethicity, parity, history
of preeclampsia, chronic
hypertension, PAPP-A, PlGF
Not stated No No Yes
(Continued)
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Table 1. (Continued)
O’Gorman
et al, 2016 [27]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated No No Yes
Pare´ et al, 2014
[28]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated No No No
Moon et al,
2015 [29]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated No No Yes
Park et al, 2013
[30]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not applicable because
this study is an external
validation of a
previously developed
prediction model
No No Yes
Kenny et al,
2014 [33]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Yes No No Yes
Poon et al,
2009 [21]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated No No Yes
Herraiz et al,
2009 [36]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated Yes. Study externally
validated a previously
developed prediction model
No Yes
Di Lorenzo
et al, 2012 [37]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated No No Yes
Goetzinger
et al, 2014 [38]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated Yes Yes Yes
Crovetto et al,
2014 [39]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated No No Yes
Gallo et al,
2016 [40]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Cross validation No No Yes
Skrastad et al,
2015 [41]
Maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Not stated Yes. Study externally
validated a previously
developed prediction model
No Yes
Antonio et al,
2017 [43]
Maternal characteristics,
biomarkers, Uterine artery
pulsatility index.
Logistic
regression
Not stated No No Yes
Parra-Cordero
et al, 2013 [24]
Maternal characteristics,
biomarkers, Uterine artery
pulsatility index.
Logistic
regression
Not stated No No Yes
Myers et al,
2013 [20]
Maternal characteristics,
biomarkers, Uterine artery
pulsatility index.
Logistic
regression
Cross validation No No Yes
Baschat et al,
2014 [46]
Maternal characteristics,
biomarkers, Uterine artery
pulsatility index.
Logistic
regression
Cross validation No No Yes
Scazzocchio
et al 2017
maternal characteristics,
serum biomarkers, uterine
artery pulsatility index
Logistic
regression
Bootstrapping Yes Yes Yes
Wright et al,
2019
maternal characteristics,
MAP, Uterine artery
pulsatility index, PlGF
Logistic
regression
Not stated Yes Yes Yes
(Continued)
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Table 1. (Continued)
Lobo et al,
2019
Maternal age, ethnicity,
smoking status, MAP,
Urerine artery pulsatility
index, PlGF, PAPP-A
Fetal Medicine
Foundation
Algorithm
Not stated Yes No Yes
Study Discrimination (AUC) Prediction rule/
score chart/
nomogram
Handling of missing
values
Model selection: Stepwise
selection, Univariate p-
values, No selection
Handling of continuous data: Kept
linear, categorized, dichotomized
Mello et al,
2002 [14]
Yes; AUC (development) =
0.984; AUC (after external
validation) = 0.892.
No Not stated Stepwise selection Categorized
Poon, et al,
2010 [34]
Yes; PE < 34 weeks:
AUC = 0.794 (0.720 to
0.869);
Model formula
with regression
coefficients
Complete case analysis Not stated Kept linear
PE� 34 weeks: AUC = 0.796
(0.761 to 0.830).
Muto et al,
2016 [42]
No Model formula
with regression
coefficients
Complete case analysis Not stated Categorized
Kuijk et al,
2014 [32]
Yes; PE< 37 weeks:
AUC = 62.4 (51.0 to 73.7).
All PE:AUC = 61.4 (51.9 to
70.9)
Model formula
with regression
coefficients, score
chart.
Regression imputation Not stated Categorized
Poon et al,
2008 [35]
Yes; AUC = 0.852. Model formula
with regression
coefficients
Complete case analysis Not stated Kept linear
Benko et al,
2019
Yes; development cohort:
AUC = 0.65 (0.60 to 0.69);
validation cohort: AUC not
stated.
Regression
coefficients
Not stated survival analysis Not stated
Boutin et al,
2018
AUC: 0.62 (0.58–0.66) No Complete case analysis Univariate p-value Not stated
Antwi et al,
2017 [47]
Yes; development cohort:
AUC = 0.70 (0.67 to 0.74);
validation cohort:
AUC = 0.68 (0.60 to 0.77).
Model formula
with regression
coefficients, score
chart.
Multiple imputation Stepwise backward selection Kept linear
Becker Rolf,
2011 [49]
No Model formula
with regression
coefficients,
algorithm.
Not stated Not stated Categorized
North et al,
2011 [48]
Yes; AUC = 0.710 (0.706 to
0.714)
Model formula
with regression
coefficients
Imputation by
expectation
maximization method.
Stepwise backward selection Kept linear, BMI categorized.
Sepulveda-
Martinez et al
2019
AUC: 0.890 (0.837–0.955) Algorithm Not stated Stepwise backward selection Not stated
Myatt L. et al,
2012 [50]
Yes; AUC = 0.73 (0.69 to
0.77).
No Complete case analysis Stepwise backward selection Kept linear
Goetzinger
et al,2010 [51]
Yes; AUC = 0.70 (0.65 to
0.72).
Model formula
with regression
coefficients
Complete case analysis Stepwise backward selection Categorized
Odibo et al,
2011 [52]
Yes; AUC = 0.77 (0.63 to
0.81).
Model formula
with regression
coefficients
Complete case analysis Stepwise backward selection Kept linear
Kuijk et al.
2011 [19]
Yes; AUC = 0.65 (0.56 to
0.74).
Model formula
with regression
coefficients
Single regression
imputation
Not stated Kept linear
(Continued)
PLOS ONE Systematic review of prediction models.
PLOS ONE | https://doi.org/10.1371/journal.pone.0230955 April 21, 2020 10 / 24
Table 1. (Continued)
Stamilio et al,
2000 [31]
Yes; AUC = 0.75. Model formula
with regression
coefficients
Complete case analysis Stepwise backward selection Categorized
Gabbay-Benziv
et al, [23]
Yes; 0.78 (0.72 to 0.85) Prediction rule Complete case analysis Not stated Categorized
Allen et al,
2017 [44]
Yes; AUC = 0.81 (0.69 to
0.93)
Model formula
with regression
coefficients
Complete case analysis Stepwise selection Kept linear
Mello et al,
2001 [45]
Yes; prediction at 16 weeks:
AUC = 0.952 (0.895 to
1.000); prediction at 20
weeks: AUC = 0.851 (0.739
to 0.941)
Model formula
with regression
coefficients
Complete case analysis Not stated Categorized
Antwi et al,
2018
AUC: 0.82 (0.74–0.89) Model formula
with regression
coefficients
Complete case analysis Stepwise backward selection Kept linear
Zhang et al,
2019
AUC for early PE: 0.90
(0.89–0.91); AUC for late PE:
0.82 (0.81–0.84)
PREDICTOR
Algorithm
Complete case analysis Not stated Not stated
O’Gorman
et al, 2016 [27]
Yes; PE< 37 weeks:
AUC = 0.907; PE�37 weeks:
AUC = 0.796.
Model formula
with regression
coefficients
Complete case analysis Stepwise backward selection Kept linear
Pare´ et al, 2014
[28]
No Model formula
with regression
coefficients
Not stated Stepwise backward selection Kept linear
Moon et al,
2015 [29]
Yes; Model nulliparous:
AUC = 0.88 (0.80 to 0.94);
Model multiparous:
AUC = 0.84 (0.75 to 0.91).
Model formula
with regression
coefficients
Complete case analysis Stepwise backward selection Not stated
Park et al, 2013
[30]
Yes; AUC = 0.926 (0.916–
0.936).
Model formula
with regression
coefficients
Complete case analysis Not stated Kept linear
Kenny et al,
2014 [33]
Yes; development cohort:
AUC = 0.73(0.70 to 0.77);
validation cohort:
AUC = 0.68(0.63 to 0.74).
Model formula
with regression
coefficients
Imputation by
expextation
maximization method,
complete case analysis
for uterine artery
pulsatility index
Stepwise backward selection Kept linear
Poon et al,
2009 [21]
No model formula
with regression
coefficients
Complete case analysis Not stated Kept linear
Herraiz et al,
2009 [36]
Yes; PE< 34 weeks:
AUC = 0.779 (0.641 to
0.917); PE 34 weeks:
AUC = 0.641 (0.481 to
0.801).
Model formula
with regression
coefficients
Not stated Not applicable Kept linear
Di Lorenzo
et al, 2012 [37]
Yes; AUC = 0.895 Model formula
with regression
coefficients
Complete case analysis Step down procedure Kept linear
Goetzinger
et al, 2014 [38]
Yes; development cohort:
AUC = 0.80 (0.73 to 0.86);
validation cohort:
AUC = 0.78 (0.69 to 0.86).
Model formula
with regression
coefficients
Complete case analysis Stepwise backward selection Categorized
Crovetto et al,
2014 [39]
Yes; AUC = 0.960 (0.919 to
0.999).
Model formula
with regression
coefficients
Not stated Stepwise forward selection Kept linear
(Continued)
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pressure and diastolic blood pressure, mean arterial pressure, maternal ethnicity, parity, previ-
ous history of preeclampsia, family history of hypertension, family history of preeclampsia, his-
tory of smoking and history of gestational diabetes mellitus. The following biomarkers were
included: uterine artery pulsatility index (UtA PI, 17/40), pregnancy associated plasma pro-
tein-A (PAPP-A) (16/40) and placental growth factor (PlGF) (16/40). The following predictors
were used less than ten times in the studies under review: free beta human chorionic gonado-
tropin (fß-HCG), alpha feto protein (AFP), soluble fms-like tyrosine kinase-1 (sFlt-1), placen-
tal protein 13 (PP13), A disintegrin and metalloproteinase 12 (ADAM12), soluble endoglin
(sEng) and vascular endothelial growth factor (VEGF). Fig 2 shows the frequency of predictor
variables in the prediction models.
Methodological quality of the studies to develop or validate prediction
models using the CHARMS, STROBE and TRIPOD checklists
Source of data. All the studies indicated the type of study design used to obtain data for
the prediction modeling. 37 were cohort studies whilst three were nested case-control studies.
Table 1. (Continued)
Gallo et al,
2016 [40]
Yes; PE<32 weeks:
AUC = 0.995 (0.990 to
0.999); PE< 32 weeks:
AUC = 0.930 (0.892 to
0.968); PE� 37 weeks:
AUC = 0.773 (0.771 to
0.805).
Model formula
with regression
coefficients
Complete case analysis Not stated Kept linear
Skrastad et al,
2015 [41]
Yes; AUC (FMF�) = 0.77
(0.67 to 0.87), AUC
(PREDICTOR¥) = 0.74
(0.63–0.84)
Fetal Medicine
Foundation
algorithm
Complete case analysis Not stated Kept linear
Antonio et al,
2017 [43]
Yes; PE <34 weeks:
AUC = 0.946 (0.919 to
0.973); PE< 37 weeks:
AUC = 0.870 (0.798 to
0.942); PE< 42 weeks:
AUC = 0.857 (0.807 to0.907)
Model formula
with regression
coefficients
Complete case analysis Not stated Kept linear
Parra-Cordero
et al, 2013 [24]
ROC curve presented but
AUC values not provided.
Model formula
with regression
coefficients
Complete case analysis Not stated Kept linear
Myers et al,
2013 [20]
Yes; AUC = 0.84 (0.77 to
0.91)
No Complete case analysis Stepwise selection (forward
selection followed by series
of backward selection)
Age and blood pressure kept linear,
BMI categorized
Baschat et al,
2014 [46]
Yes; PE < 34 weeks:
AUC = 0.83 (0.74 to 0.91); all
PE: AUC = 0.82 (0.78 to
0.86).
Model formula
with regression
coefficients
Complete case analysis Lasso logistic regression Categorized
Scazzocchio
et al, 2017
Early onset PE AUC = 0.94
(95% CI, 0.88–0.99), late
onset PE AUC = 0.72 (95%
CI, 0.66–0.77)
Regression
coefficients
Not stated Not stated Not stated
Wright et al,
2019
Early PE:AUC = 0.95 (0.93–
0.97); Pretem PE = 0.91
(0.89–0.91); All PE = 0.83
(0.81–0.84)
Algorithm Not stated Not stated Not stated
Lobo et al,
2019
Preterm PE AUC:0.94 (0.92–
0.97); Term PE AUC: 0.87
(0.79–094)
FMF Algorithm Complete case analysis Not stated Not stated
https://doi.org/10.1371/journal.pone.0230955.t001
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Participants. All the studies indicated the participant eligibility and recruitment criteria,
including the study location, number of centres and the inclusion and exclusion criteria.
Outcomes to be predicted. All the studies gave a standard definition for the outcome(s)
to be predicted. Most of the studies had a single outcome while eleven studies had two or more
outcomes.
Candidate predictors. All the studies defined and described the candidate predictors and
the methods for their measurement. The timing of predictor measurements was also provided
in all studies. Handling of predictors in the modeling process was described by 31 out of the 40
studies. Nine of the studies categorized continuous variables whilst 21 studies kept continuous
variables linear.
Sample size. All studies provided the number of participants and the number of out-
comes. Only nine of the studies explicitly estimated the sample size before the onset of the
study. The number of outcomes in relation to the number of candidate predictors (events per
variable) were deduced from the data and ranged between 2.1 and 88.2.
Missing data. The number of participants with any missing value for each predictor was
not provided by the studies. Nine of the studies did not indicate how missing data were han-
dled. Complete case analysis was used by 26 out of the 40 studies whilst five studies imputed
missing data using the single regression imputation method [19,32], expectation maximization
method [33,48] and multiple imputation [47].
Model development. All the studies selected candidate predictors for inclusion in the
model through univariate analysis using a pre-determined p-value. Logistic regression and
survival modelling were used to derive the prediction models. For selection of predictors dur-
ing multivariable modeling, one study used the stepwise forward selection method, 14 studies
Fig 2. Frequency of predictor variables in the prediction models.
https://doi.org/10.1371/journal.pone.0230955.g002
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used the stepwise backward selection method and two studies used stepwise selection without
further specification. One study [46] applied the Lasso regression approach and another sur-
vival analysis whilst 21 studies did not state the method used for deriving the model.
Model performance. Discrimination of the prediction models, depicted by the c-statistic
or the area under the receiver operating characteristic (ROC) curve was reported by 34 (85%)
of the studies while calibration was reported by five (12.5%) studies. Classification measures
were reported by 37 (92.5%) of the studies (Table 1).
Model evaluation
Internal and external validation. Internal validation was reported by eleven out of 40
studies, using bootstrapping [19,47,54,60], cross validation [14,20,40,46,48], split sample [61]
and back propagation of error method for artificial neural networks [45]. Nine out of the 40
prediction models were externally validated.
Risk of bias assessment. Risk of bias refers to the extent that flaws in the design, conduct,
and analysis of the primary prediction modelling study lead to biased, often overly optimistic,
estimates of predictive performance measures such as model calibration, discrimination, or
(re)classification (usually due to overfitted models).
Fig 3 shows the risk of bias assessment of the studies. Most of the studies had a low risk of
bias. The major source of bias related to sample size estimations, only stated in detail by nine
out of 40 studies.
Details of the risk of bias assessment are presented in Table 2.
Prediction models applicable in low and middle income settings. Apart from two mod-
els each from Brazil and Chile, both Upper middle income countries in Latin America, and
two models from Ghana, all the other models in the literature that met our inclusion criteria
Fig 3. Risk of bias assessment of the prediction studies.
https://doi.org/10.1371/journal.pone.0230955.g003
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were developed in high income countries of Europe, Japan, Australia, New Zealand, China,
Canada and the United States of America.
Meta-analysis. The forest plot of the meta-analysis of the prediction models for preeclamp-
sia is presented in Fig 4. The I2 was 99%. Overall area under the curve was 0.79 (0.75–0.84).
Discussion
We set out to review the evidence in the published literature on the performance of multivari-
ate prediction models for gestational hypertension and preeclampsia to assess the effectiveness
of prediction models in identifying pregnant women at risk for gestational hypertension and
preeclampsia. The specific objectives of this study were to identify prediction models for gesta-
tional hypertension and preeclampsia in the literature, assess the methodological quality of the
prediction modeling studies by applying the CHARMS checklist and identify prediction mod-
els that can be applied in low and middle income country settings.
Prediction models for gestational hypertension and preeclampsia
Our study identified 40 prediction models for gestational hypertension and preeclampsia,
most of which had been developed and validated in high-income countries in Europe,
Fig 4. Forest plot of prediction models for preeclampsia.
https://doi.org/10.1371/journal.pone.0230955.g004
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Australia and the USA. Only two of such studies had been conducted in a low and middle
income country setting. Most of the prediction models were developed in single centres but a
few had been developed using data from multiple centres in one or more countries.
Methodological quality of prediction modeling studies
The STROBE (Strengthening the reporting of observational studies in epidemiology), TRI-
POD (Transparent reporting of a multivariable prediction model for individual prognosis or
diagnosis) and the CHARMS checklists have outlined steps for developing and validating pre-
diction models. The CHARMS checklist in particular provides guidance as to the items to
extract when conducting a systematic review of prediction studies. An assessment of the meth-
ods used in model development in the studies evaluated in this review showed gaps in applica-
tion of recommendations in the CHARMS, TRIPOD and STROBE checklists. The following
domains of the CHARMS checklist were not adequately addressed in most of the studies: the
source of data, study participants, outcome(s) to be predicted, candidate predictors, sample
size, missing data, model development, model performance, model evaluation, results, inter-
pretation and discussion. For example continuous predictors were dichotomized in some of
the studies despite evidence and recommendations to the contrary [62–65]. Bias in predictor
selection is known to occur when continuous predictors are categorized. Again, categorizing
continuous variables assumes that there is a stepwise change in risk from one cut-off point to
another. Bodnar et al [66] have demonstrated a dose-dependent relationship between pre-
pregnancy BMI and the risk of preeclampsia. As BMI increases, so does the risk of preeclamp-
sia. Therefore categorizing the predictor variable makes the functional relationship between
the continuous variable (predictor) and the outcome variable linear, hence nonlinear transfor-
mations such as restricted cubic splines or fractional polynomials cannot be applied [62,67,68].
To prevent overestimation of risks by prediction models, it is recommended that the number
of outcomes in relation to the number of predictors (events-per-variable) should be at least ten to
one [69,70]. This requires an adequate sample size that ensures that there are enough outcomes in
the study. Hence sample size estimation is an important methodological consideration so that at
the onset of the study an adequate events-per-variable can be assured and thereby prevent overes-
timation of the predictive performance of the models (overfitting). Unfortunately, most of the
studies under review did not report on sample size estimation. An adequate sample size also mini-
mizes predictor selection bias. Predictor selection bias tends to be greater in smaller datasets when
the events-per-variable ratio is small, especially when there are weak predictors in the dataset [16].
Information on missing data should be reported as part of the results of the studies. This
includes the number of participants with any missing value (including values for both predic-
tors and outcomes), number of participants with missing data for each predictor and how the
missing data were handled, for example by complete case analysis, imputation or other meth-
ods. Information about missing data gives an idea as to the extent of bias, dependent on the
reasons for the missing data. Where data were not missing completely at random, the predic-
tion estimates are likely to be biased [64,71–75]. Missing data are seldom missing completely
at random and may often be related to other observed participant data. Consequently, partici-
pants with completely observed data are likely to be different from those with missing data.
Complete-case analysis which was the commonest method used to handle missing data in
most studies deletes participants with a missing value from the analysis, thereby resulting in
loss of information from a subset of the study population. This may result in over or under
estimation of the predictive effect and reduced performance in an external population.
Prediction model performance is one of the important domains to be in the reported on
[71]. Model performance indicators include calibration, discrimination and classification. It is
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recommended that discrimination and calibration should always be reported for prediction
models. Discrimination indicates how well the prediction model distinguishes between two
outcomes such as disease or non-disease and is assessed using the c-statistic or the area-under-
the-curve (AUC) of a receiver operating characteristic curve [76–78]. The AUC ranges from
0.5 to 1 and represents the prediction model’s ability to correctly classify a randomly selected
individual as being from one of two hypothetical populations [78–81]. An AUC value of 1.0 is
considered perfect, 0.9–0.99 excellent, 0.8–0.89 good, 0.7–0.79 fair and 0.51–0.69 poor. An
AUC of 0.5 is considered non-informative. The AUC in the studies under review ranged
between 0.65 and 0.98. Apart from the study by Kuijk et al [19] which had an AUC of 0.65, all
the other studies reported AUC greater than or equal to 0.70, indicating good to excellent dis-
crimination. Calibration refers to how well the predicted risks compare to the observed out-
comes. Usually this is evaluated in a calibration plot by graphically plotting observed against
predicted event rates [16,67,82]. Calibration plots may be supplemented by the Hosmer-Leme-
show test, which is a formal statistical test to determine whether calibration is adequate. Unfor-
tunately most of the studies under review did not report the calibration plot. This shortcoming
leaves room for uncertainty in applying the model in clinical practice because one cannot
determine the probability range within which the model works well. Both discrimination and
calibration are essential in determining model performance.
Prediction model evaluation can be undertaken by internal validation (using the same data-
set as that used to develop the model) and external validation (using a different dataset to that
used in developing the model). The external dataset should be collected using the same predic-
tor and outcome definitions and measurements. Again most of the studies did not report
whether or not internal validation had been performed thus breaching an important methodo-
logical consideration. Most of the studies did not follow the guidelines in the TRIPOD,
STROBE and CHARMS checklists. A possible explanation may be that some of studies were
conducted prior to the development of these guidelines so the investigators may not have had
the benefit of these methodological guidelines.
Prediction models applicable in low and middle income settings
Only five of the studies had been conducted in a low-and-middle income country setting.
Given contextual differences between high and low-and-middle income countries, many of
the prediction models under review which have been developed in high income countries at
present may not be applicable in most low-and-middle income countries. This is because these
prediction models included biomarkers and uterine artery pulsatility index as predictors in
addition to maternal clinical characteristics [20,21,23,24,27,28,30,36–41,44,46,48–52,61,83]. At
present uterine Doppler measurement and serum biomarker assays are not widely available in
many low-and-middle income countries. Therefore prediction models using biomarkers and
uterine artery pulsatility index may not be routinely applied in these settings.
Generally, prediction models developed in one setting have to be externally validated in
new populations to assess their performance before applying them in clinical decision-making.
The model intercept and the regression coefficients often have to be updated to fit the new
context or population to which the prediction model is being applied to. Thus prediction mod-
els developed elsewhere may be updated for use in other settings provided the predictors and
outcome are the same. In situations where a prediction model includes variables which cannot
be measured in the setting where the model is to be applied, that model cannot be used in that
population. Consequently most prediction models developed in high income countries and
including variables like serum biomarkers and uterine artery pulsatility index are at present
not applicable in most low-and-middle income countries where the burden of hypertensive
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disorders of pregnancy is greater. Presently prediction models using maternal clinical charac-
teristics, and which give optimum predictions can be externally validated and applied in low
resource settings.
Conclusion
Most of the studies evaluated did not completely follow the CHARMS, TRIPOD and STROBE
guidelines in prediction model development and reporting. Adherence to these guidelines will
improve prediction modelling studies and subsequent application of prediction models in clin-
ical practice. Prediction models using maternal characteristics, with good discrimination and
calibration, should be externally validated for use in low and middle income countries where
biomarker assays are not routinely available.
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